Guideline Recommendations for Comprehensive History Taking in Systemic Lupus Erythematosus

Overall Impact of Structured History

• A systematic assessment of disease activity across all organ systems, together with screening for cardiovascular and infection risks, evaluation of treatment‑related complications, and quality‑of‑life appraisal, directly reduces morbidity and mortality in SLE patients. [1][2]

Constitutional & Quality‑of‑Life Assessment

• Fatigue should be quantified at every visit using a 0–10 visual analog scale, as it is the most prevalent symptom affecting patients’ quality of life. 1
• The overall impact of disease on daily activities, household responsibilities, and work capacity must be documented to evaluate functional status. 1

Mucocutaneous Evaluation

• Skin lesions should be classified as lupus‑specific, lupus‑non‑specific, lupus mimickers, or drug‑related to guide appropriate management. 2

Neuropsychiatric Screening

• Screen for a history of seizures and for headache patterns (frequency, severity, associated features). 2
• Actively inquire about cognitive dysfunction, including difficulties with multitasking, household tasks, memory, attention/concentration, and word‑finding. 2
• Assess for mood disorders, particularly depression. 2
• Evaluate peripheral neuropathy symptoms such as numbness, tingling, or weakness. 2

Obstetric & Gynecologic Considerations

• Document the use of oral contraceptives or other hormonal therapies, as they influence cardiovascular risk in women with SLE. 1

Cardiovascular Risk Assessment

• Recognize that SLE patients experience accelerated atherosclerosis and increased cardiovascular mortality that cannot be fully explained by traditional risk factors alone. 1
• Record smoking status (current, former, pack‑years). 1
• Document any prior vascular events (myocardial infarction, stroke, peripheral arterial disease). 1
• Assess physical activity level and sedentary behavior. 1
• Obtain a family history of premature cardiovascular disease. 1
• Screen for diabetes symptoms and known diagnosis. 1
• Document known hypertension and its control status. 1
• Record a history of dyslipidemia. 1

Osteoporosis Risk Evaluation

• Assess dietary and supplemental calcium and vitamin D intake. [1][3]
• Document exercise habits, emphasizing weight‑bearing activity. 1
• Inquire about a history of fractures, particularly vertebral or hip fractures. 1
• Ask about sun‑avoidance behaviors that may contribute to vitamin D deficiency. 1
• Osteoporosis prevalence in SLE ranges from 4 % to 24 %, with vertebral fractures occurring in 7.6 %–37 % of patients. [1][3]

Medication History & Drug Toxicity Monitoring

• List all current immunosuppressive agents, including dose and duration. 1
• Record glucocorticoid exposure (current dose, cumulative exposure, highest ever dose). [1][2]
• Document hydroxychloroquine use and duration to stratify retinopathy risk. [2][4]
• Record antimalarial use and the date of the most recent ophthalmology examination. [2][4]
• Note any cyclophosphamide exposure for appropriate cancer‑screening follow‑up. 1

Cancer Screening Recommendations

• Recognize that SLE is associated with increased incidence of hematologic malignancies, cervical, breast, and lung cancers. [1][3]
• Verify the date of the last cervical cytology test; abnormal results occur in up to 16 % of SLE patients. [1][3]
• Ensure age‑appropriate mammography is up to date. 1
• Confirm age‑appropriate colonoscopy screening status. 1
• Despite higher cancer risk, SLE patients undergo screening less frequently than the general population. [1][3]

Disease Activity Monitoring

• At each visit, ask about any new or worsening symptoms in any organ system since the previous appointment. 1

Systemic Lupus Erythematosus Evaluation Guidelines

Introduction to SLE Evaluation

• The European League Against Rheumatism recommends characterizing mucocutaneous lesions as LE-specific, LE-nonspecific, LE mimickers, or drug-related 5
• The European League Against Rheumatism emphasizes cardiovascular risk screening as SLE patients have accelerated atherosclerosis 6

Mucocutaneous and Renal Systems

• The European League Against Rheumatism specifically recommends focused history for mucocutaneous symptoms, including discoid lesions and subacute cutaneous lupus lesions 5
• Edema, foamy urine, hematuria, and changes in urinary frequency or volume should be asked about, as these are relevant to renal symptoms in SLE patients 5
• Hypertension symptoms, such as headaches and vision changes, should be documented 5

Neuropsychiatric System

• The European League Against Rheumatism specifically recommends focused history for neuropsychological symptoms, including seizures, headaches, cognitive dysfunction, mood disorders, peripheral neuropathy, and stroke symptoms 5
• Cognitive dysfunction, including problems with multitasking, difficulty with household tasks, memory problems, attention and concentration difficulties, and word-finding difficulties, should be specifically asked about 5

Hematologic and Cardiovascular Systems

• Thrombosis history, including any history of blood clots, should be documented 5
• The European League Against Rheumatism emphasizes the importance of identifying antiphospholipid syndrome, which significantly increases morbidity and mortality 5
• Arterial thrombosis, including stroke, TIA, and myocardial infarction at a young age, should be asked about 5
• Venous thrombosis, including DVT and PE, should be inquired about 5

Obstetric/Gynecologic History and Medication Exposures

• Pregnancy complications, including recurrent miscarriages, preeclampsia, intrauterine growth restriction, and stillbirths, should be specifically asked about 5
• Drug-induced lupus, including medications known to trigger lupus-like syndromes, should be asked about 5

Cardiovascular Risk Assessment

• Smoking status, history of vascular events, physical activity level, use of oral contraceptives/hormonal therapies, and family history of cardiovascular disease should be assessed 6
• Infection risk factors should be assessed, as infections are a major cause of morbidity and mortality in SLE patients 6